NEW YORK, NY / ACCESSWIRE / September 17, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Greenlane Holdings, Inc. (GNLN)
Lawsuit on behalf of: investors who purchased on behalf of all who purchased or otherwise acquired Greenlane common stock pursuant or traceable to the registration statement and prospectus issued in connection with Greenlane’s April 2019 initial public offering.
Lead Plaintiff Deadline : November 12, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/greenlane-loss-form?prid=3546&wire=1
According to the filed complaint, (1) the City of San Francisco had introduced a major initiative to ban the sale of e-cigarette products across three major cities and prohibit the manufacture of products at the headquarters of Greenlane’s key partner, JUUL Labs; (2) if approved, the initiative would materially and adversely impact the Company’s financial results and prospects; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Curaleaf Holdings, Inc. (CURLF)
Lawsuit on behalf of: investors who purchased November 21, 2018 - July 22, 2019
Lead Plaintiff Deadline : October 4, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/curaleaf-holdings-inc-loss-form?prid=3546&wire=1
According to the filed complaint, during the class period, Curaleaf Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
CVS Health Corporation (CVS)
Lawsuit on behalf of: investors who purchased on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS’s acquisition of Aetna on November 28, 2018.
Lead Plaintiff Deadline : October 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cvs-health-corporation-loss-form-2?prid=3546&wire=1
According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose that: (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: